Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 5, 2021
Grant Date -
Feb 1, 2018
app pub date -
Oct 13, 2017
filing date -
Dec 14, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
- 2017 Application Filing Year
- A61K Class
- 21227 Applications Filed
- 12841 Patents Issued To-Date
- 60.50 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 4 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Apr 5, 2025 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Apr 5, 2029 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Apr 5, 2033 |
